United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) - diazoxide oral suspension is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. infants and children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. diazoxide oral suspension should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. when other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide oral suspension should be considered. the use of diazoxide oral suspension for functional hypoglycemia is contraindicated. the drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh

United States - English - NLM (National Library of Medicine)

e5 pharma, llc - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) - diazoxide oral suspension is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: - adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. - infants and children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. diazoxide should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. when other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide should be considered. the use of diazoxide for functional hypoglycemia is contraindicated. the drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh the possible risks.

United States - English - NLM (National Library of Medicine)

trirx huntsville pharmaceutical services llc - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) -

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) - diazoxide 50 mg in 1 ml - proglycem (oral diazoxide) is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. infants and children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. proglycem may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. proglycem should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. when other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with proglycem should be considered. the use of proglycem for functional hypoglycemia is contraindicated. the drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh the possible risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - diazoxide, quantity: 15 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - diazoxide is a non-diuretic antihypertensive agent. it is administered by rapid iv injection for emergency reduction of blood pressure in patients with malignant hypertension when prompt and urgent decrease in diastolic pressure is required. diazoxide injection bp is recommended in the treatment of hypertensive crises associated with acute glomerular nephritis, acute hypertensive encephalopathy, cerebral haemorrhage or congestive heart failure. diazoxide is usually effective in patients with refractory hypertension not responsive to other agents. it has also been used in the treatment of chronic hypertension to control elevated blood pressure before commencement of therapy with oral antihypertensive agents. in order to reduce the danger of haemorrhage due to elevated blood pressure, diazoxide injection bp may be used in hypertensive patients undergoing diagnostic procedures such as renal biopsy or arteriography

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - diazoxide -

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

orphanpacific,inc. - diazoxide - clear and colorless capsule/ white powder/ major axis: approx. 15.8 mm, no. 3 capsule

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - diazoxide 15 mg/ml - solution for injection - 300 mg/20ml - active: diazoxide 15 mg/ml excipient: sodium hydroxide water for injection

United States - English - NLM (National Library of Medicine)

truemed group llc - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) -